Back to top
more

IDEXX Laboratories (IDXX)

(Delayed Data from NSDQ)

$650.06 USD

650.06
798,784

+25.87 (4.14%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $650.31 +0.25 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

4 Top Growth Picks to Avoid Tax Tangle in MedTech

by Zacks Equity Research

Despite the ongoing tax bill-related disputes in the MedTech industry, these stocks with high growth potential can be great bets for investors.

    Zacks Equity Research

    IDEXX Laboratories (IDXX) Q3 Earnings Beat, Revenues Miss

    by Zacks Equity Research

    IDEXX Laboratories (IDXX) rides high on strength in Companion Animal Group business in Q3. Moreover, a raised guidance buoys optimism.

      Zacks Equity Research

      IDEXX Laboratories (IDXX) Beats on Q3 Earnings, View Up

      by Zacks Equity Research

      IDEXX Laboratories (IDXX) gains on solid contributions from Companion Animal Group business in Q3.

        Zacks Equity Research

        Should You Buy IDEXX Laboratories (IDXX) Ahead of Earnings?

        by Zacks Equity Research

        IDEXX Laboratories (IDXX) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

          Zacks Equity Research

          PetMed (PETS) Tops Q2 Earnings & Sales Estimates, Margins Up

          by Zacks Equity Research

          The year-over-year rise in earnings of PetMed (PETS) was driven by an increase in sales and improved margins.

            Zacks Equity Research

            Can Companion Animal Group Drive IDEXX's (IDXX) Q3 Earnings?

            by Zacks Equity Research

            IDEXX Laboratories (IDXX) is poised to gain from strength in its Companion Animal Group business in Q3.

              Zacks Equity Research

              Abbott (ABT) Exceeds Q3 Earnings, '17 Guidance Narrowed

              by Zacks Equity Research

              Abbott (ABT) posted promising Q3 results primarily on the back of strong EPD sales and emerging market expansion.

                Zacks Equity Research

                Phibro Animal Banks on Diverse Portfolio, Competition Rife

                by Zacks Equity Research

                Phibro Animal (PAHC) is consistently trying to expand its product portfolio to counter the tough competition in the animal health space.

                  Zacks Equity Research

                  Henry Schein (HSIC) Inks Distribution Agreement with Terason

                  by Zacks Equity Research

                  Henry Schein's (HSIC) distribution agreement with Terason to distribute the latter's uSmart 3200T NexGen is likely to boost its global Medical segment business.

                    Zacks Equity Research

                    Here's Why You Should Buy Thermo Fisher Scientific (TMO) Now

                    by Zacks Equity Research

                    Based on a wide range of fundamental factors, Thermo Fisher (TMO) is a great pick for now.

                      Zacks Equity Research

                      Here's Why Investors Should Buy Integra LifeSciences Now

                      by Zacks Equity Research

                      The market is upbeat about Integra LifeSciences' (IART) latest developments that include product launches and strategic buyouts.

                        Zacks Equity Research

                        TransEnterix Senhance Surgical Robotic System Wins FDA Nod

                        by Zacks Equity Research

                        TransEnterix (TRXC) works on expanding in robotic surgery consistently.

                          Zacks Equity Research

                          Henry Schein Gains on Strategic Buyouts, Cost Concern a Woe

                          by Zacks Equity Research

                          Henry Schein (HSIC) continues to grow on dental and animal health business, thanks to merger and acquisition activity. However, rising costs continue to be a burden on the company's bottom line.

                            Zacks Equity Research

                            NuVasive's (NUVA) PRECICE System Gets Expanded FDA Approval

                            by Zacks Equity Research

                            NuVasive's (NUVA) latest receipt of expanded FDA 510(k) approval for PRECICE is likely to fortify its hold in the limb reconstruction and trauma market.

                              Zacks Equity Research

                              Here's Why Investors Should Sell Ecolab (ECL) Right Away

                              by Zacks Equity Research

                              Intensifying competition, foreign exchange volatility, higher raw material costs and integration risks are primary headwinds for Ecolab (ECL) as of now.

                                Zacks Equity Research

                                Abbott Banks on FDA Approvals and Buyouts, Competition Rife

                                by Zacks Equity Research

                                The market is upbeat about Abbott's (ABT) latest initiatives.

                                  Zacks Equity Research

                                  Bruker (BRKR) at a 52-Week High: What's Driving the Stock?

                                  by Zacks Equity Research

                                  The new 52-week high of Bruker (BRKR) came on the back of several new initiatives, the most recent one being the introduction of the new CE-IVD marked Fungiplex Candida fast diagnostic assay.

                                    Zacks Equity Research

                                    OPKO Health (OPK) Signs New Agreement with Japan Tobacco

                                    by Zacks Equity Research

                                    OPKO Health's (OPK) new agreement with Japan Tobacco will enhance prospects of its kidney drug RAYALDEE in Japan.

                                      Zacks Equity Research

                                      LabCorp (LH) Strong on Strategic Planning, Competition Rife

                                      by Zacks Equity Research

                                      LabCorp (LH) grows on strong diagnostics business amid softness in the Covance drug development business.

                                        Zacks Equity Research

                                        DENTSPLY SIRONA Strong on Deal Renewals, Forex Woes Stay

                                        by Zacks Equity Research

                                        DENTSPLY SIRONA's (XRAY) renewed distribution deal will aid the company to gain market traction. However, forex woes remain a concern.

                                          Zacks Equity Research

                                          Ecolab (ECL) to Divest Equipment Care Segment, Shares Fall

                                          by Zacks Equity Research

                                          In August, management at Ecolab (ECL) announced that equipment care business has been witnessing a quiet period, registering just 2% growth on a year-over-year basis in the last quarter.

                                            Zacks Equity Research

                                            Veeva Systems (VEEV) Rides High on Commercial Cloud Platform

                                            by Zacks Equity Research

                                            The cost-effectiveness of cloud-based applications over in-premise applications is attracting life science companies. Veeva's (VEEV) industry-specific focus lends it a significant leverage.

                                              Zacks Equity Research

                                              Henry Schein Closes Merritt Buyout, Expands in Animal Health

                                              by Zacks Equity Research

                                              Henry Schein (HSIC) is consistently trying to expand its Animal Health business.

                                                Zacks Equity Research

                                                CryoLife to Buy JOTEC, Preliminary Revenue Result Out for Q3

                                                by Zacks Equity Research

                                                CryoLife (CRY) gained access to the $2-billion global market for stent grafts through JOTEC deal.

                                                  Zacks Equity Research

                                                  Mazor Projects Higher Q3 Revenues, Clinches Mazor X Orders

                                                  by Zacks Equity Research

                                                  Mazor's (MZOR) strong booking and order backlog from Mazor X system sales is likely to boost fortunes in the global spine surgery space.